567 related articles for article (PubMed ID: 25789661)
1. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.
Glund S; Moschetti V; Norris S; Stangier J; Schmohl M; van Ryn J; Lang B; Ramael S; Reilly P
Thromb Haemost; 2015 May; 113(5):943-51. PubMed ID: 25789661
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
[TBL] [Abstract][Full Text] [Related]
3. Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study.
Wang Z; Zhao X; He P; Chen S; Jiang J; Harada A; Brooks S; Cui Y
Adv Ther; 2020 Sep; 37(9):3916-3928. PubMed ID: 32691242
[TBL] [Abstract][Full Text] [Related]
4. Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
Glund S; Stangier J; van Ryn J; Schmohl M; Moschetti V; Haazen W; De Smet M; Gansser D; Norris S; Lang B; Reilly P; Kreuzer J
Clin Pharmacokinet; 2017 Jan; 56(1):41-54. PubMed ID: 27317414
[TBL] [Abstract][Full Text] [Related]
5. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
[TBL] [Abstract][Full Text] [Related]
6. Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran.
Miyares MA; Kuyumjian Y; Eaves S; Dollard E
J Pharm Pract; 2015 Dec; 28(6):548-54. PubMed ID: 26894245
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
8. Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
Honickel M; Spronk HM; Rossaint R; Stoppe C; van Ryn J; Ten Cate H; Grottke O
Thromb Haemost; 2017 Jun; 117(7):1370-1378. PubMed ID: 28424818
[TBL] [Abstract][Full Text] [Related]
9. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
[TBL] [Abstract][Full Text] [Related]
10. Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers.
Schmohl M; Glund S; Harada A; Imazu S; De Smet M; Moschetti V; Ramael S; Ikushima I; Grünenfelder F; Reilly P; Stangier J
Thromb Haemost; 2017 Jan; 117(2):269-276. PubMed ID: 27904905
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study.
Yasaka M; Ikushima I; Harada A; Imazu S; Taniguchi A; Norris S; Gansser D; Stangier J; Schmohl M; Reilly PA
Res Pract Thromb Haemost; 2017 Oct; 1(2):202-215. PubMed ID: 30046691
[TBL] [Abstract][Full Text] [Related]
12. Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report.
Tireli D; He J; Nordling MM; Wienecke T
J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):e123-e125. PubMed ID: 28479184
[TBL] [Abstract][Full Text] [Related]
13. Idarucizumab for Dabigatran Reversal.
Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
[TBL] [Abstract][Full Text] [Related]
14. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
Norris S; Ramael S; Ikushima I; Haazen W; Harada A; Moschetti V; Imazu S; Reilly PA; Lang B; Stangier J; Glund S
Br J Clin Pharmacol; 2017 Aug; 83(8):1815-1825. PubMed ID: 28230262
[TBL] [Abstract][Full Text] [Related]
16. Reversal of dabigatran by intraosseous or intravenous idarucizumab in a porcine polytrauma model.
Akman N; Braunschweig T; Honickel M; Schütt K; Schöchl H; Stoppe C; Rossaint R; Grottke O
Br J Anaesth; 2018 May; 120(5):978-987. PubMed ID: 29661415
[TBL] [Abstract][Full Text] [Related]
17. Reversal of dabigatran by idarucizumab: when and how?
Vanassche T; Greinacher A; Verhamme P
Expert Rev Hematol; 2016 Jun; 9(6):519-28. PubMed ID: 27166653
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
Sié P
Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
[TBL] [Abstract][Full Text] [Related]
19. The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination.
Glund S; Gan G; Moschetti V; Reilly P; Honickel M; Grottke O; Van Ryn J
Clin Appl Thromb Hemost; 2018 Jul; 24(5):724-733. PubMed ID: 29534609
[TBL] [Abstract][Full Text] [Related]
20. Idarucizumab: A Review as a Reversal Agent for Dabigatran.
Syed YY
Am J Cardiovasc Drugs; 2016 Aug; 16(4):297-304. PubMed ID: 27388764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
